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Abstract
High serum adiponectin has been increased in several conditions of kidney disease. Only
sparse and conflicting results have been reported in patients with type 2 diabetes (T2D), a
subgroup of individuals who are at high risk for renal dysfunction. The aim of this study was
to fill up this gap of knowledge by investigating such association in a large sample of Italian
diabetic patients. The association between serum adiponectin levels and estimated glomer-
ular filtration rate (eGFR by Chronic Kidney Disease-Epidemiology Collaboration CKD-EPI
equation) was investigated in 1,243 patients with T2D from two cross-sectional Italian stud-
ies: 878 from San Giovanni Rotondo (SGR) and 365 from Foggia (FG). Serum adiponectin
was inversely associated with eGFR in SGR [β (standard error, SE) for 1 standard deviation
(SD) of adiponectin = -3.26 (0.64)] and in FG [β(SE)=-5.70(1.28)] sample, as well as in the
two studies combined [β(SE)=-3.99(0.59)];(p<0.0001 for all). In this combined analysis, the
association was still significant after adjusting for sex, smoking habits, body mass index
(BMI), waist circumference, diabetes duration, glycated hemoglobin (HbA1c), albumin
creatinine ratio (ACR) and anti-hyperglycemic, anti-hypertensive and anti-dyslipidemic
treatments [β (SE)= -2.19 (0.59), p = 0.0001]. A stronger association between each SD adi-
ponectin increment and low eGFR was observed among patients with micro-/macro-albu-
minuria, as compared to those with normo-albuminuria [adjusted β(SE)=-4.42(1.16) ml/min/
1.73m2 vs. -1.50 (0.67) ml/min/1.73m2, respectively; p for adiponectin-by-albuminuric status
= 0.022]. For each adiponectin SD increment, the odds of having eGFR < 60 ml/min/1.73m2
increased by 41% (odds ratio, OR = 1.41; 95% confidence interval, CI 1.21–1.64) in SGR
sample, 53% (OR = 1.53; 95% CI 1.21–1.94) in FG sample, and 44% (OR = 1.44; 95%CI
1.27–1.64) in the two studies considered together (p<0.0001 for all). In the combined sam-
ple, further adjustment for the above mentioned covariates did not change the observed
association (OR = 1.36; 95%CI 1.16–1.60; p<0.0001). Our study, so far the largest address-
ing the relationship between serum adiponectin and GFR in T2D, strongly suggests that
the paradoxical inverse association, previously reported in different clinical sets, is also
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observed in diabetic patients. Further studies are needed to unravel the biology underlying
this counterintuitive relationship.
Introduction
Chronic kidney disease (CKD), mainly indicated by a reduced glomerular filtration rate (GFR),
is the leading cause of premature death in patients and type 2 diabetes (T2D) [1–3]. A better
understanding of pathogenic mechanisms responsible for GFR decline in T2D is, therefore,
urgently needed.
Quite surprisingly, given its beneficial effect on insulin resistance and its anti-inflammatory
[4, 5] and anti-oxidative stress [6] properties, circulating adiponectin, a 30 kDa adipokine
exclusively secreted by adipocytes in humans [7, 8], is increased in several conditions of kidney
disease. Results of the many, often quite small, studies reporting this finding have been prop-
erly reviewed [9–11]. Along the same line, a similar counterintuitive association has been
reported also in patients with coronary artery disease [12], type 1 diabetes [13–15] and in non
diabetic individuals as well [16, 17], but not in individuals with GFR 60 ml/min/1.73 m2
from a population-based Japanese cohort [18]. Despite T2D is strongly characterized by adipo-
cytokines dysregulation [19, 20] and represents one of the most important risk factor for kid-
ney disease [21], no clear data on the relationship between adiponectin and GFR in such
condition are available. In details, data on T2D have been mostly obtained in small studies
[22–30] whose results are, overall, conflicting, ranging from a direct relationship [25], to no
association at all [23, 26, 27, 30], or to an inverse association [22, 24, 28, 29] between adiponec-
tin and kidney function.
To gain further insights into this subject, we analyzed the relationship between serum adi-
ponectin levels and eGFR in more than 1,200 patients with T2D from Central Southern Italy
were studied by a cross-sectional design.
Subjects and Methods
Two independent samples here investigated were recruited from geographically close centers
and with identical inclusion and exclusion criteria, thus minimizing possible resulting
heterogeneity.
The San Giovanni Rotondo (SGR) sample
Baseline values of 878 subjects with T2D (defined according to the ADA 2003 criteria) from
Gargano (Southern-Centre Italy) were used for this study. They are part of the Gargano Mor-
tality Study, a cohort of consecutively recruited diabetic patients used for prospective investiga-
tion on determinants of all-cause mortality in T2D. The general features of this study have
been previously described [31–33].
The Foggia (FG) sample
Baseline values of 365 subjects with T2D (defined according to the ADA 2003 criteria) from
Foggia (Southern-Centre Italy) were used for this study. They are part of the Foggia Mortality
Study, a cohort of consecutively recruited diabetic patients used for prospective investigation
on determinants of all-cause mortality in T2D. The general features of this study have been
previously described [31, 32].
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Data Collection and Definitions
Clinical data were obtained from a standardized interview and examination. Body mass index
(BMI) was calculated by dividing the weight (in kilograms) by squared height (in meters).
Hypertension was defined as a systolic blood pressure was> 130 mmHg or diastolic blood
pressure was> 85 mmHg or presence of antihypertensive therapy. Smoking habits, dyslipide-
mia (as indicated by the presence of lipid-lowering therapy), and anti-hyperglycemic treatment
were also recorded at the time of examination. Data regarding medications were confirmed by
review of medical records. Individuals who reported smoking cigarettes regularly during the
year before the examination were considered current smokers. Diabetes duration was calcu-
lated from the current age and the age at diagnosis of diabetes.
In the two studies, blood samples were collected between 8:00 and 9:00 AM after an over-
night fast. Serum aliquots were stored at -80°C.
HbA1c was measured, using a HPLC Diamat Analyzer (Bio-Rad, Richmond, CA).
Standardized serum creatinine was measured with the modified kinetic Jaffè reaction (Hita-
chi 737Autoanalyzer, Tokyo, Japan). The serum creatinine methods had been calibrated to be
traceable to an isotope dilution mass spectrometry (IDMS) reference method.
Urinary albumin and creatinine concentrations were determined the same morning of the
clinical examination on an early morning first-void sterile urine sample by the Nephelometric
method (Nephelometer Analyser; Behring, Germany) and the Jaffe’s reaction-rate method,
respectively.
By study design [31, 32], all these variables were assessed at recruitment the same morning
of clinical examination.
Estimated GFR was then assessed by CKD-EPI equation [34].
Increased albuminuria was diagnosed if the urinary albumin/creatinine ratio (ACR)
was 2.5 mg/mmol in men and 3.5 mg/mmol in women.
Presence of urinary tract infections was considered as an exclusion criterion.
Ethics
The study protocols and the informed consent procedures were approved by the Institutional
Ethic Committee of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) ‘‘Casa Sollievo
della Sofferenza” and of University of Foggia. All participants gave written informed consent.
Measurement of Circulating Adiponectin Levels
Serum adiponectin concentrations were measured by a commercial ELISA (Alpco, Salem, NH)
at the Research Unit of Diabetes and Endocrine Diseases at ‘‘Casa Sollievo della Sofferenza”, as
previously described [35]. Inter- and intra-assay coefficients of variation were 7.0 and 6.6%,
respectively. The minimum detection limit was 0.019 ng/ml.
Statistical Methods
Patients’ baseline characteristics are reported as mean ± standard deviation (SD) and percent-
ages for continuous and categorical variables, respectively.
Baseline comparisons between groups were performed using Pearson χ2 test for categorical
variables, T-test and ANOVA models for normal-distributed continuous variables and Mann-
Whitney U test for skewed-distributed continuous variables. To determine normal/no normal
distribution Kolgomorov-Smirnorv test was performed.
The association between adiponectin levels and eGFR (i.e. the dependent variable) as a con-
tinuous trait was investigated by univariate and multivariable linear regression analysis after
Adiponectin and Kidney Function in Type 2 Diabetes
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logarithm transformation. Covariates were sex, smoking habits, BMI, waist circumference, dia-
betes duration, HbA1c, ACR, anti-hyperglycemic anti-hypertensive and anti-dyslipidemic
treatments. Age was not used as a covariate because it is already included in the CKD-EPI for-
mula and also because of its collinearity with disease duration.
Results were reported as linear model coefficients along with their standard errors [β (SE)].
The association between adiponectin levels and eGFR as a dichotomous trait (i.e. or< 60
ml/min/1.73m2) was tested by logistic regression analysis. Results were reported as ORs, along
with their 95% CI.
Random effect meta-analysis was performed in an individual patient data meta-analysis
fashion [36] after checking for heterogeneity (i.e. the presence of a significant exposure-by-
sample interaction).
A p-value< 0.05 was considered as significant. All analyses were performed using SPSS
v.15 (SPSS, Chicago IL) and SAS Release 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Patients’ clinical features in both samples are shown in Table 1.
The two samples were quite different in terms of most clinical variables (p<0.05) but, sex,
anti-hyperglycemic treatment and adiponectin levels.
When eGFR was analyzed as a continuous trait, an inverse association between serum adi-
ponectin and eGFR was obtained: β (SE) for each SD increase of adiponectin level = -3.26
(0.64) ml/min/1.73m2 in SGR study; -5.70 (1.28) ml/min/1.73m2 in FG study and -3.99 (0.59)
ml/min/1.73m2 in the two studies combined; with a p value less than 0.0001 for all of them
(Table 2).
These associations were still significant after adjusting for several variables we were able to
account for, all possibly influencing renal function: sex, smoking habits, BMI, waist circumference,
Table 1. Clinical characteristics of patients from SGR and FG studies.
SGR (N = 878) FG (N = 365)
Sex (males %) 456 (51.9) 201 (55.1)
Age (yrs) 61.8±9.6 63.3±11.2
Smokers (%) 128 (14.6) 68 (18.6)
BMI (kg/m2) 30.9±5.6 29.7±5.8
Waist circumference (cm) 102.2±13.5 105.3±14.4
Diabetes duration (yrs) 10.7±8.9 13.4±10.2
HbA1c (%) 8.7±2.0 9.0±2.1
Anti-hyperglycemic treatment (%) 733 (83.5) 323 (88.5)
- Oral agents 368 (41.9) 176 (48.2)
- Insulin w/wo oral agents (%) 365 (41.6) 147 (40.3)
ACE/RAS treatment (%) 360 (49.7) 230 (63.0)
Statins treatment (%) 263 (30.0) 135 (37.0)
Micro-/macro-albuminuria (%) 248 (29.8) 155 (43.1)
eGFR (ml/min/1.73m2) 73.6±19.1 80.9±25.1
Adiponectin (μg/ml) 6.0 ± 3.6 5.8±3.6
Continuous variables were reported as mean ± SD whereas categorical variables were reported as total
frequency and percentages. SGR: San Giovanni Rotondo; FG: Foggia; BMI: Body Mass Index; HbA1c:
glycated hemoglobin;, ACE/RAS: angiotensin-converting enzyme/renin-angiotensin system; eGFR:
estimated glomerular filtration rate.
doi:10.1371/journal.pone.0140631.t001
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diabetes duration, HbA1c, ACR and anti-diabetic, anti-hypertensive and anti-dyslipidemic thera-
pies (Table 2).
In the combined analysis, the association between serum adiponectin and eGFR was clearly
different in patients with normo-albuminuria as compared to those with micro-/macro-albu-
minuria [adjusted β (SE) for each SD increase of adiponectin level = -1.50 (0.67) and -4.42
(1.16) ml/min/1.73m2, respectively, p = 0.002 for both; p for adiponectin-by-albuminuric status
interaction = 0.022]. In contrast, no difference in the association between adiponectin and
eGFR was observed in patients with micro- as compared to those with macro-albuminuria (p
for adiponectin-by-albuminuric status interaction = 0.30) as well as in men as compared to
women (p for adiponectin-by-sex interaction = 0.74).
When eGFR was analyzed as a dichotomous trait of clinical significance (i.e.
eGFR< or 60 ml/min/1.73m2), adiponectin levels were higher in patients with lower eGFR
in both SGR (n = 175; 7.1±4.1 vs. n = 703; 5.7±3.4) and FG (n = 73; 7.1±3.2 vs. n = 292; 5.4
±3.6), as well as in the two studies combined (n = 248; 7.1±3.9 vs. n = 995; 5.6±3.4). For each
SD increment in adiponectin levels, the odds of eGFR< 60 ml/min/1.73m2 was significantly
increased in SGR, FG and in the two studies combined (Table 3).
Table 2. Association between serum adiponectin levels and eGFR, considered as a continuous trait.
SGR (N = 878) FG sample (N = 365) Pooled data meta-analysis
(N = 1,243)*
β (SE) P β (SE) P β (SE) P
Model 1 -3.26 (0.64) <0.0001 -5.70 (1.28) <0.0001 -3.99 (0.59) <0.0001
Model 2 -1.22 (0.65) 0.037 -3.91 (1.21) 0.003 -2.19 (0.59) 0.0001
SGR: San Giovanni Rotondo; FG: Foggia. p value obtained from lnGFR.
The β linear coefficients represent the change in eGFR level (ml/min/1.73m2) for 1.SD increase in adiponectin. SE: standard error.
Model 1: unadjusted.
Model 2: adjusted by sex, smoking habits, BMI, waist circumference, diabetes duration, HbA1c, ACR and anti-hyperglycemic, anti-hypertensive and anti-
dyslipidemic treatments.
*Since the effect in SGR tended to be different than that in FG sample (p for β values heterogeneity being = 0.15), individual data meta-analysis was
carried out in a conservative fashion by using random effects.
Pooled analysis were adjusted by study sample.
doi:10.1371/journal.pone.0140631.t002
Table 3. Association between serum adiponectin levels and low GFR (< 60ml/min/1.73m2).
SGR sample (N = 878) FG sample (N = 365) Pooled data meta-analysis
(N = 1,243)*
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Model 1 1.41 (1.21–1.64) <0.0001 1.53 (1.21–1.94) <0.0001 1.44 (1.27–1.64) <0.0001
Model 2 1.31 (1.08–1.60) 0.007 1.53 (1.14–2.04) 0.004 1.36 (1.16–1.60) <0.0001
SGR: San Giovanni Rotondo; FG: Foggia;
OR (95% CI) are given for 1 SD increase of adiponectin levels.
Model 1: unadjusted.
Model 2: adjusted by sex, smoking habits, BMI, waist circumference, diabetes duration, HbA1c, ACR and anti-hyperglycemic, anti-hypertensive and anti-
dyslipidemic treatments.
*Since the effect in SGR was not different than that in FG sample (p for OR values heterogeneity being = 0.56), individual data meta-analysis was carried
out by using fixed effects.
Pooled analysis were adjusted by study sample.
doi:10.1371/journal.pone.0140631.t003
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Also in this case such associations remained significant after adjusting for the several covari-
ates mentioned above (Table 3).
Discussion
This study, comprising more than 1,200 Italian patients with T2D, shows an inverse relation-
ship between adiponectin levels and GFR. Such counterintuitive association is independent of
many confounders we were able to account for.
Previous studies on the relationship between adiponectin and kidney function in T2D have
been thus far contradictory [22–30], with some reporting a direct relationship in men (i.e.
toward the opposite direction we here report) [25], some reporting no association at all [23, 26,
27, 30], and finally some others describing an inverse association [22, 24, 28, 29], like the one
we observed. Unfortunately, most of these studies were carried out in small samples, which
definitively lacked the power for drawing firm conclusions [24, 28, 29] or in non-European
populations [22], thus leaving unaddressed the association between adiponectin and kidney
function among European patients with T2D. So, our study, thanks to the large number of
individuals who were investigated, says a strong word on this subject, definitively indicating
that a paradoxical association between serum adiponectin and kidney function is observable
also among patients with T2D of European origin.
It is of note that such association was similar in men and women, thus making difficult to
reconcile our data with those reported in a previous study, carried out only in men and report-
ing an association toward the opposite direction we here observed [25].
By its intrinsic nature, our observational study does not allow to draw firm conclusions
about the possible mechanism(s) underlying this paradoxical association. We can only hypoth-
esize, that in individuals with kidney dysfunction, increased levels of circulating adiponectin,
rather than being only a mere effect of decreased renal excretion, represent a tentative homeo-
static mechanism aimed at counteracting, through anti-inflammatory and anti-oxidative stress
mechanisms [4–6], renal damage [37, 38]. Animal studies have in fact reported that adiponec-
tin retards the progression of diabetic nephropathy [39, 40]. Such a scenario might be also
exacerbated by a reduced response to adiponectin biological effects, as suggested by the recent
observations of a post receptor adiponectin resistance, paralleled by increased adiponectin and
adiponectin receptor 1 gene expression, in peripheral tissues from humans with severe kidney
dysfunction [41, 42].
An additional result of our study is that the negative correlation between adiponectin and
GFR levels is more evident in patients with micro-/macro-albuminuria as compared with those
with normo-albuminuria. How micro-/macro-albuminuria exacerbates the negative correla-
tion between serum adiponectin and GFR is not known. Overall, the stronger association
observed in the presence of an additional condition of kidney dysfunction (i.e. increased albu-
minuria), reinforces the hypothesis of a tentative, protective role of adiponectin as a mecha-
nism underlying its inverse counterintuitive relationship with GFR.
Strengths of our study are the overall sample size, consisting of a total of 1,243 diabetic
patients all from the same geographical region and the fact that all samples were handled iden-
tically, with measurement of serum adiponectin being centralized.
Conversely, the lack of information on specific classes of anti-hyperglycemic drugs has to be
recognized as a limitation.
Despite the two study samples have been recruited from a geographically homogeneous
region and with identical inclusion/exclusion criteria, some differences in baseline clinical fea-
tures emerged. Being aware that such differences might have played a role in the association
Adiponectin and Kidney Function in Type 2 Diabetes
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between adiponectin and kidney function, we were conservative enough to use random-effect
in the pooled meta-analysis, thus taking into account possible across samples heterogeneity.
In addition, it is not known whether our present finding is generalizable to other popula-
tions of European ancestry with different environmental and/or genetic backgrounds, both fac-
tors known to modulate serum adiponectin concentrations [35, 43].
In conclusion, our data clearly show, that there is an inverse and independent association
between serum adiponectin and GFR among Italian patients with T2D. Further studies are
warranted to examine the exact mechanisms underlying this counterintuitive relationship and
to explore the potential role of adiponectin as a tool for improving prediction, prevention and
treatment strategies aimed at reducing the burden of kidney function loss in such high risk
individuals.
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